Neurology Development Articles & Analysis
21 news found
“Our business model is driven by an understanding that scalable infrastructures, like those we have and are developing, are an indispensable prerequisite to foster clinical accessibility, affordability, and market penetration of precision medicine tools,” said Dr. ...
She added, “As medicine moves towards personalized care, more precise cell recovery is required for research and pharmaceutical development, especially in the new fields of cell therapeutics and genomics. ...
AoP exposes these delicate neonates to repeated episodes of hypoxemia which is shown to increase risk of mortality in the NICU as well as short and long-term impaired neurological development. Orphan Drug Designation is granted to drugs or biological products for the treatment of rare diseases or conditions that impact fewer than 200,000 people in the United ...
Approval for post-operative respiratory depression expected in 2026, and community drug overdose thereafter. ENA-001 is also being developed in an Intramuscular (“IM”) Formulation in partnership with the Biomedical Advanced Research and Development Authority (“BARDA”) (contract number 75A50121C00044) for the potential use in patients ...
Chadha is a medical doctor and internationally recognized expert in clinical pathology, neuroscience, neurological disease, and psychiatric disorders. She brings decades of global experience in clinical research and development, commercialization, patient engagement, and regulatory strategy. ...
Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that it has successfully raised an additional $14 million for its Series A round with new and existing investors. ...
VeriSIM Life (VeriSIM), the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced that it has entered into a partnership agreement with Total Brain, an applied, integrative neuroscience company, to create breakthrough neurodata-driven actionable insights for developing novel drugs to ...
Founded in 2015 in Barcelona, Catalonia, Spain, Molomics integrates AI with Human Collective Intelligence (HCI) to determine novel chemical structures with high therapeutic activity and superior pharmacological properties as developed or marketed drugs. Molomics has used this approach toward advancing the treatment of Parkinson's Disease to develop a drug that ...
This collaboration is expected to identify biomarkers of response to refine patient selection to guide and accelerate the clinical development of Cyclerion’s investigational therapeutics for neurological and neuropsychiatric diseases associated with cognitive impairment. ...
In the studies, the team of researchers developed an innovative mouse model system to evaluate the effects of the gut microbiome-derived metabolite 4-ethylphenol sulfate (4EPS) on complex behaviors and brain function. ...
Enalare is planning to develop this unique agnostic respiratory stimulant for a multitude of indications related to acute respiratory depression, including for neonates experiencing Apnea of Prematurity. ...
Leblond, in collaboration with Kevin Petrecca, director of the brain tumour research program and chief of neurosurgery at the Montreal Neurological Institute-Hospital, developed a hand-held probe using Raman spectroscopy to distinguish cancer from healthy tissue. ...
Austin, TX, September 27, 2021 -- Veravas, Inc., an early-stage diagnostics company, has announced the development of its VeraPrep™ Antibody Detection Kit, a new development platform that provides scientists with a state-of-the-art research tool to easily and quickly develop new tests to multiplex detect and measure immunoglobulins against ...
The five finalist companies are developing medical technology innovations in cardiology, pulmonology, mental health, and neurology: cellvie is developing a device-enabled mitochondria transplantation therapy for heart disease. The company is based in Düsseldorf, Germany. Circadia Health is developing a contactless remote ...
Biotech company NeuroScientific Biopharmaceuticals is on the cutting-edge of developing pharmaceutical solutions for neurological disorders and is dedicated to world-class science that improve patient's lives Biotech company NeuroScientific Biopharmaceuticals is on the cutting-edge of developing pharmaceutical solutions for ...
Since 2011, a team at the Cleveland Clinic Neurological Institute has been researching the consequences of concussions. Led by Jay Alberts, director of the Clinic’s Concussion Center and a member of the biomedical engineering staff at the Neurological Institute, the team has developed a mobile app called Cleveland Clinic Concussion App ...
Chemicals which disrupt the hormone system – also known as 'endocrine disrupting chemicals' (EDCs) – may be a contributing factor behind the significant increases in cancers, diabetes and obesity, falling fertility, and an increased number of neurological development problems in both humans and animals, according to a review of recent scientific ...
These include initiatives to encourage federal procurement of an expanded range of biobased products; take better advantage of large pharmaceutical data sets to speed drug development; apply the latest genomics discoveries to identify quickly emerging microbial threats; and accelerate research on non-embryonic stem cells as possible treatments for blood-related and ...
These include initiatives to encourage federal procurement of an expanded range of biobased products; take better advantage of large pharmaceutical data sets to speed drug development; apply the latest genomics discoveries to identify quickly emerging microbial threats; and accelerate research on non-embryonic stem cells as possible treatments for blood-related and ...
These include initiatives to encourage federal procurement of an expanded range of biobased products; take better advantage of large pharmaceutical data sets to speed drug development; apply the latest genomics discoveries to identify quickly emerging microbial threats; and accelerate research on non-embryonic stem cells as possible treatments for blood-related and ...